UBS raises Aptive price target to $82, maintains Buy rating
UBS analyst Joseph Spak increased the price target for Aptive PLC (NYSE:APTV) to $82 from the previous $73, while retaining a Buy rating on the stock. Currently trading at $64.13, Aptiv appears ...
bovnews1m
The Boston Scientific Corp Stock Thriller: Decoding the Mystery Behind BSX’s Recent Movements
Boston Scientific Corp (BSX) stock saw a decline, ending the day at $100.31 which represents a decrease of $-0.60 or -0.59% from the prior close of $100.91. The stock opened at $100.91 and touched a ...
UBS lifts Teva stock price target to $30, maintains Buy rating
UBS analyst Ashwani Verma increased the price target for Teva Pharmaceutical Industries Ltd (NYSE:TEVA) to $30 from the previous $28 while keeping a Buy rating on the shares. Verma highlighted Teva as ...